Yi‐Lin Chiu
AbbVie (United States)(US)National Defense Medical Center(TW)
Publications by Year
Research Areas
HIV/AIDS drug development and treatment, Gastroesophageal reflux and treatments, Chronic Lymphocytic Leukemia Research, Protist diversity and phylogeny, Microtubule and mitosis dynamics
Most-Cited Works
- → Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity(2010)845 cited
- → Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors(2011)582 cited
- → The Tablet Formulation of Lopinavir/Ritonavir Provides Similar Bioavailability to the Soft-Gelatin Capsule Formulation With Less Pharmacokinetic Variability and Diminished Food Effect(2007)151 cited
- → Serum Adalimumab Concentration and Clinical Remission in Patients with Crohnʼs Disease(2013)122 cited
- → A Once-Daily Lopinavir/Ritonavir-Based Regimen Provides Noninferior Antiviral Activity Compared With a Twice-Daily Regimen(2006)119 cited
- → Presenting Symptoms of Nonerosive and Erosive Esophagitis in Pediatric Patients(2006)72 cited